Theralase(R) Investor Conference Call Reminder

Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company's ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") ("Study II"), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025.

Participants are encouraged to submit questions in advance to [e-mail] to ensure sufficient time for discussion.

Zoom Meeting Link: https://us02web.zoom.us/j/81044841120
Webinar ID: 810 4484 1120

Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom

An archived version will be available on the website following the conference call.

Study II Update:

As of November 7, 2025:

• 88 patients have been treated with the primary Study Procedure, representing 97.8% of the targeted enrollment of 90 patients
• 72 patients have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response
• 16 patients remain pending study completion

Interim Clinical Results Demonstrate:

• 64.3% (54/84) of patients achieved a Complete Response ("CR") at any point in time.
• 72.6% (61/84) achieved a Total Response (TR = CR + Indeterminate Response ("IR")).
• At the 450-day assessment,
  • 40% (18/45) of patients maintained a CR
  • 42.2% (19/45) maintained a TR, demonstrating durability of response.

Theralase® remains on track to complete enrollment in 4Q2025, with data lock and regulatory submissions expected in 1Q2027.

Financial Update:

Theralase® has released its unaudited, condensed, consolidated, interim 3Q2025 financial statements for the period ended September 30, 2025.

Financial Highlights - Nine Months Ended September 30, 2025 versus 2024:

• Revenue decreased 5% to $590,573 from $622,984.
• Cost of sales decreased 10% to $299,743 (51% of revenue).
• Gross margin remained stable at $290,830 (49% of revenue).
• Selling expenses decreased 18% to $212,421.
• Administrative expenses increased 12% to $1,444,687.
• Research and development expenses increased 1% to $2,116,540, reflecting increased activity to support Study II progress.
• Net loss increased 3% to $3,435,145, including $708,521 in non-cash expenses such as amortization and stock-based compensation.

Operational Highlights: